News Daily News Coronary Sinus Reducer Overlooked in Review of Stable Angina Treatments Michael O'Riordan January 03, 2025
News Conference News ACC 2024 Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC Michael O'Riordan April 08, 2024
Presentation ACC 2024 Coronary Sinus Reducer for the treatment of refractory angina: a randomised, placebo-controlled trial (ORBITA-COSMIC) Presenter: Rasha K. Al-Lamee April 08, 2024
News Conference News AHA 2023 Placebo-Controlled ORBITA-2 Shows PCI Eases Symptoms in Stable Angina Michael O'Riordan November 11, 2023
News Conference News EuroPCR 2023 Meta-analysis Finds No Excess Mortality Risk With Coronary Revascularization Michael O'Riordan May 19, 2023
News Daily News COURAGE and ORBITA Had No Impact on Elective PCI Rates in UK Michael O'Riordan September 15, 2022
News Daily News Optimal Medical Therapy for Stable Angina: Which Drugs? How Long? Michael O'Riordan January 25, 2022
News Conference News EuroPCR 2021 Elective Revascularization, Better Long-term Survival: Meta-analysis Michael O'Riordan May 18, 2021
News Conference News EuroPCR 2020 No Survival Benefit With Revascularization in Stable CAD, Meta-analysis Confirms Michael O'Riordan June 26, 2020
News Conference News AHA 2019 More Ischemia on Stress Echo Equals Greater Angina Benefit With PCI: ORBITA Michael O'Riordan November 14, 2019
News Conference News EuroPCR 2018 New ORBITA Insights: Invasive Physiology Tests Track Closely With Ischemia, but Not Symptom Improvement Shelley Wood May 22, 2018
News Features ISCHEMIA Fracas: Amid Charges of Moving the Goalposts, Investigators Come Out Swinging Michael O'Riordan March 23, 2018
News Conference News ACC 2018 ACC 2018: More PCSK9 Outcomes, Antiplatelet Insights, and LifeVest Data at Last Shelley Wood March 05, 2018
News Daily News Year in Review: Physicians Pick the Biggest News of 2017, in Interventional Cardiology and Beyond Shelley Wood December 26, 2017
News Opinion Editor's Corner TCTMD’s Top 10 Most Popular Stories for November 2017 Shelley Wood November 29, 2017
News Features Trajectory Unknown: How ORBITA Lands in Clinical Practice Still Up for Debate Michael O'Riordan November 27, 2017